相关实验视频
Updated: Jun 30, 2025
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.1K
托法西提尼布和阿达利穆马布在轴性脊椎关节炎中的比较有效性:现实世界的临床背景多中心研究
Rudra Prosad Goswami1, Debanjali Sinha2, Moumita Chatterjee3
1From the Department of Rheumatology, All India Institute of Medical Sciences (AIIMS), New Delhi.
概括
托法西提尼布在六个月后在轴性脊椎关节炎 (AxSpA) 治疗中表现出与阿达利穆马布 (adalimumab) 相似的有效性. 虽然最初的反应有利于阿达利穆马布,但托法西提尼布提供了有利的药物成本效益比率.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 轴性脊椎关节炎 (AxSpA) 是一种慢性炎症性疾病.
- 托法西提尼布是一种口服的Janus激酶抑制剂,正在考虑用于AxSpA治疗.
- 阿达利穆马布是一种常用于AxSpA的生物疗法.
研究的目的:
- 在AxSpA患者中,比较托法西提尼布与阿达利穆马布的实际有效性和耐受性.
- 评估与两种治疗相关的疾病活性得分和药物成本.
主要方法:
- 一个多中心的医疗记录审查的成年AxSpA患者治疗托法西提尼布5毫克两次或阿达利穆马布40毫克每两周.
- 评估的有效性是使用性脊髓炎疾病活动指数 (ASDAS) 和浴性脊髓炎疾病活动指数 (BASDAI).
- 使用增量成本效益比率 (ICER药物) 进行的药物成本分析.
主要成果:
- 在六个月后,在阿达利穆马布和托法西提尼布组之间,BASDAI和ASDAS的可比平均改善.
- 在BASDAI50和ASDAS低疾病活性方面,阿达利马布的初始响应率较高.
- 更高比例的托法西替尼患者需要改变治疗 (14.8%vs7.6%).
结论:
- 托法西提尼布在六个月的AxSpA治疗效果上与阿达利穆马布相似.
- 托法西提尼布表现出有利的增量成本效益比率 (ICER药物).
- 虽然最初的反应较慢,但托法西提尼布为AxSpA管理提供了具有成本效益的选择.
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
01:20The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
163
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
163